We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Valeant Offers $296 Million for Dendreon’s Prostate Cancer Drug Provenge, Other Assets
Valeant Offers $296 Million for Dendreon’s Prostate Cancer Drug Provenge, Other Assets
Canadian drugmaker Valeant Pharmaceuticals has agreed to pay $296 million to acquire cash-strapped Dendreon’s prostate-cancer drug Provenge and other assets.